THE DEPUTY MINISTER IN THE MINISTRY OF HEALTH AND FAMILY WELFARE AND DEPUTY MINISTER IN THE MINISTRY OF INDUSTRY (SHRI DASAI CHOW-DHARY): (a) to (c) Yes, Sir. CPWD is already engaged for the Construction of the building.

Study of MAPE

556. SHRIMATI RATAN KUMARI: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) on what basis his Ministry increased MAPE;

(b) whether any study of post manufacturing expenses was taken up before or after the commencement of DPCO, 1987;

(c) what are the actual constituents of these expenses as per the records maintained by the producers;

(d) on what basis 100 per cent increase in conversion cost and packing charges was recommended by norms committee; and

(e) who examined the recommendations of committee in his Ministry?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) and (b) The increase in the MAPE under the Drugs (Prices Control) Order, 1987 is based on the measures announced by the Government in 1986.

(c) MAPE covers profit, trade mar gin, distribution expenses, promotional expenses, etc.

(d) and (e) The recommendations of the norms Committee were accepted by the Government keeping in view the increase in costs that had taken place after May, 1979.

BICP Recommendations for Bulk Drugs and Formulations

557. SHRIMATI RATAN KUMARI: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) what are the duties and responsiblities of the BICP in regard to prices of bulk drugs and formulations;

(b) whether it is a fact that his Ministry has found a number of anomalies in the findings of BICP;

(c) whether the anomalies have been brought to the notice of the Ministry of Industry;

(d) if so, when and if not, what are the reasons therefor; and

(e) what are the names of bulk drugs and formulations in respect of which BICP have failed to send its findings?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIA MENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) to (e) In the Pharmaceutical sector BICP conducts the cost-cum-technical studies of the bulk drugs for the purpose of price fixation. It also works out the price of formulations based on various parameters in the DPCO. BICP is a recommendatory body and the final decision on the price is taken by the Government. The Government may not accept all its recommendations based on additional information which may be available with the Government and further clarification from BICP. Of 143 bulk drugs under price control about 78 bulk drugs have been studied by the BICP so far.

Prices of drug formulations

558. SHRIMATI RATAN KUMARI: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) whether his Ministry has maintained any records relating to formu-lations for which prices have not been